The autoinjector is based on core technology licensed from Bespak. UCB announced that EMA’s Committee for Medicinal Products for Human Use (CHMP) has recommended the use of Cimzia (certolizumab pegol) ...

A self-injection pen prefilled with Brussels-based UCB’s Cimzia (certolizumab pegol) has been made available this week in the U.K. after a positive opinion from the EMA. UCB developed the AutoClicks ...

Consort Medical plc ("Consort Medical", "Consort" or the "Group") (LSE: CSRT), notes the announcement from UCB, dated 26 October 2016, that the new certolizumab pegol (Cimzia®) AutoClicks® prefilled ...

"The FDA approval of CIMZIA for adults with non-radiographic axial spondyloarthritis will be transformative for the many patients living with this disease," said Emmanuel Caeymaex, Head of Immunology ...

Cost regulators for the NHS in England and Wales are backing UCB's Cimzia and Novartis' Cosentyx as treatment options for adults with active psoriatic arthritis. Cost regulators for the NHS in England ...

BRUSSELS, June 26 (Reuters) - Europe's drug watchdog has recommended EU approval of UCB SA's Cimzia drug as a treatment for rheumatoid arthritis, the Belgian company said on Friday, clearing the way ...

UCB announced today that it received approval from Japanese health authorities for CIMZIA® (certolizumab pegol) to treat plaque psoriasis, psoriatic arthritis, pustular psoriasis and psoriatic ...

UCB announced results from its PRECiSE 3 (PEGylated antibody fragment evaluation in Crohn’s disease: safety and efficacy) clinical trial for Cimzia (certolizumab pegol) in patients with moderate to ...

LONDON (Reuters) - Cimzia stops structural damage to joints in patients with rheumatoid arthritis as soon as 16 weeks after the start of treatment, according to new data presented on Thursday. The ...

In UCB, Inc. v. Yeda Research and Development Co., the Federal Circuit affirmed the determination by the District Court for the Eastern District of Virginia that UCB, Inc.’s Cimzia® (certolizumab ...